Increased aggregation of human platelets produced by advanced glycation end products in vitro

被引:58
作者
Hangaishi, M
Taguchi, J
Miyata, T
Ikari, Y
Togo, M
Hashimoto, Y
Watanabe, T
Kimura, S
Kurokawa, K
Ohno, M
机构
[1] Univ Tokyo, Fac Med, Dept Internal Med 1, Tokyo 113, Japan
[2] Tokai Univ, Fac Med, Dept Internal Med, Isehara, Kanagawa, Japan
关键词
D O I
10.1006/bbrc.1998.8945
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Advanced glyco-oxidation end products (AGEs) generate oxygen free radicals that potentiate the development of atherosclerosis. Thus, AGEs may potentiate the aggregation of human platelets through oxidative stress. AGE-bovine serum albumin (BSA) and AGE-poly-L-lysine were evaluated for aggregation of human platelets. Superoxide in platelet-rich plasma (PRP) was measured using lucigenin-derived chemiluminescence. The platelet aggregation induced by ADP or U46619 was potentiated by preincubation with AGE-BSA, by 40% and by 59%, P <.05, respectively, vs BSA. Aggregation was increased by AGEs in a dose-dependent manner. The production of superoxide was significantly greater in PRP incubated with AGE-BSA vs BSA. The other Maillard reaction products, such as Amadori-, pentosidine-, and carboxymethyl lysine (CML)-BSA had no effect. Superoxide dismutase or indomethacin abolished the enhancing effect of AGEs on the platelet aggregation. AGEs potentiate platelet aggregation possibly with superoxide anions and prostanoids. AGE-induced potentiation of platelet aggregation may be involved in the development of atherosclerosis. (C) 1998 Academic Press.
引用
收藏
页码:285 / 292
页数:8
相关论文
共 49 条
[1]   ROLE OF OXIDATIVE STRESS IN DEVELOPMENT OF COMPLICATIONS IN DIABETES [J].
BAYNES, JW .
DIABETES, 1991, 40 (04) :405-412
[2]   INTERLEUKIN-1 INDUCES PROSTACYCLIN-DEPENDENT INCREASES IN CYCLIC-AMP PRODUCTION AND DOES NOT AFFECT CYCLIC-GMP PRODUCTION IN HUMAN VASCULAR SMOOTH-MUSCLE CELLS [J].
BEASLEY, D ;
MCGUIGGIN, ME .
CYTOKINE, 1995, 7 (05) :417-426
[3]   DIABETIC LATE COMPLICATIONS - WILL ALDOSE REDUCTASE INHIBITORS OR INHIBITORS OF ADVANCED GLYCOSYLATION ENDPRODUCT FORMATION HOLD PROMISE [J].
BOEL, E ;
SELMER, J ;
FLODGAARD, HJ ;
JENSEN, T .
JOURNAL OF DIABETES AND ITS COMPLICATIONS, 1995, 9 (02) :104-129
[4]  
BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315
[5]   THE EFFECT OF LOW-DENSITY LIPOPROTEINS ON THE SYNTHESIS OF CYCLIC-NUCLEOTIDES INDUCED BY PROSTACYCLIN IN ISOLATED PLATELETS [J].
BRUCKDORFER, KR ;
BUCKLEY, S ;
HASSALL, DG .
BIOCHEMICAL JOURNAL, 1984, 223 (01) :189-196
[6]   Advanced glycosylation end products in diabetic renal and vascular disease [J].
Bucala, R ;
Vlassara, H .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1995, 26 (06) :875-888
[7]   MODIFICATION OF LOW-DENSITY-LIPOPROTEIN BY ADVANCED GLYCATION END-PRODUCTS CONTRIBUTES TO THE DYSLIPIDEMIA OF DIABETES AND RENAL-INSUFFICIENCY [J].
BUCALA, R ;
MAKITA, Z ;
VEGA, G ;
GRUNDY, S ;
KOSCHINSKY, T ;
CERAMI, A ;
VLASSARA, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (20) :9441-9445
[8]   ADVANCED GLYCOSYLATION PRODUCTS QUENCH NITRIC-OXIDE AND MEDIATE DEFECTIVE ENDOTHELIUM-DEPENDENT VASODILATATION IN EXPERIMENTAL DIABETES [J].
BUCALA, R ;
TRACEY, KJ ;
CERAMI, A .
JOURNAL OF CLINICAL INVESTIGATION, 1991, 87 (02) :432-438
[9]  
CLEMMONS RM, 1985, AM J VET RES, V46, P1104
[10]   The serum concentration of the advanced glycation end-product N-epsilon-(carboxymethyl)lysine is increased in uremia [J].
Degenhardt, TP ;
Grass, L ;
Reddy, S ;
Thorpe, SR ;
Diamandis, EP ;
Baynes, JW .
KIDNEY INTERNATIONAL, 1997, 52 (04) :1064-1067